The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals
Abstract
To assess the association of CYP2B6 allelic diversity with efavirenz (EFV) pharmacokinetics, we performed extensive genotyping of 15 relevant single nucleotide polymorphism in 169 study participants, and full resequencing of CYP2B6 in individuals with abnormal EFV plasma levels. Seventy-seven (45.5%) individuals carried a known (CYP2B6*6, *11, *15, or *18) or new loss/diminished-function alleles. Resequencing defined two new loss-of-function alleles: allele *27 (marked by 593T>C [M198T]), that results in 85% decrease in enzyme activity and allele *28 (marked by 1132C>T), that results in protein truncation at arginine 378. Median AUC levels were 188.5 microg h/ml for individuals homozygous for a loss/diminished-function allele, 58.6 microg h/ml for carriers, and 43.7 microg h/ml for noncarriers (P<0.0001). Individuals with a poor metabolizer genotype had a likelihood ratio of 35 (95% CI, 11-110) of presenting very high EFV plasma levels. CYP2B6 poor metabolizer genotypes explain to a large extent EFV pharmacokinetics and identify individuals at risk of extremely elevated EFV plasma levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482 · cited 2×
“Total protein concentration of the microsomal fraction was determined according to the method of Smith et al.(30) using bovine serum as a standard.”
MethodCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Self-citationThe Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6043 · Cited by 668
Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Hulgan, T., Marzolini, C., & Acosta, E. P. (2004) · PubMed · Cited by 627
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Self-citationLamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., Fackenthal, J. D., Rogan, P. K., Ring, B., Wrighton, S. A., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054866 · Cited by 400
Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., & Keirns, J. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14960-4 · Cited by 277
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Self-citationCsajka, C., Marzolini, C., Fattinger, K., Décosterd, L. A., Fellay, J., Telenti, A., Biollaz, J., & Buclin, T. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.22 · Cited by 266
Self-citationBupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U. M., M??rdter, T. E., Roots, I., & Brockm??ller, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00005 · Cited by 249
Self-citationGenetic variation in eleven phase I drug metabolism genes in an ethnically diverse population
Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P., Steward, J. Q., McMunn, C., Ihrie, P., Mehall, J. M., Edwards, T. L., & Dawson, E. P. (2004) · Pharmacogenomics · doi:10.1517/14622416.5.7.895 · Cited by 236
Jain, V. K., & Magrath, I. T. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90278-2 · Cited by 216
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
Xie, H.-J., Yasar, Ü., Lundgren, S., Griskevicius, L., Terelius, Y., Hassan, M., & Rane, A. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500157 · Cited by 215
Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., & LeCluyse, E. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212482200 · Cited by 215
Burger, D., Van Der Heiden, I., La Porte, C., Van Der Ende, M., Groeneveld, P., Richter, C., Koopmans, P., Kroon, F., Sprenger, H., Lindemans, J., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02536.x · Cited by 209
Hesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., Moltke, L. L., Greenblatt, D. J., & Court, M. H. (2004) · Pharmacogenetics · doi:10.1097/00008571-200404000-00002 · Cited by 193
Yamano, S., Nhamburo, P. T., Aoyama, T., Meyer, U. A., Inaba, T., Kalow, W., Gelboin, H. V., McBride, O. W., & Gonzalez, F. J. (1989) · Biochemistry · doi:10.1021/bi00444a029 · Cited by 159
Functional Characterization of Cytochrome P450 2B6 Allelic Variants
Jinno, H., Tanaka‐Kagawa, T., Ohno, A., Makino, Y., Matsushima, E., Hanioka, N., & Ando, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.398 · Cited by 152
Ariyoshi, N., Miyazaki, M., Toide, K., Sawamura, Y.-I., & Kamataki, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4524 · Cited by 140
Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068973 · Cited by 133
Self-citationWang, D., Papp, A. C., Binkley, P. F., Johnson, J. A., & Sadée, W. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230119.34205.8a · Cited by 116
Zukunft, J., Lang, T., Richter, T., Hirsch‐Ernst, K. I., Nussler, A. K., Klein, K., Schwab, M. G., Eichelbaum, M. F., & Zanger, U. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008086 · Cited by 105
Self-citationLoboz, K. K., Gross, A. S., WILLIAMS, K., Liauw, W., Day, R. O., Blievernicht, J., Zanger, U. M., & McLachlan, A. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.010 · Cited by 98
Self-citationMotsinger‐Reif, A. A., Ritchie, M. D., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., Wilkinson, G. R., Clifford, D. B., D’Aquila, R. T., Johnson, V. A., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230413.97596.fa · Cited by 67
Pharmacogenetics of HIV therapy
Owen, A., Pirmohamed, M., Khoo, S., & Back, D. J. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000236338.41799.57 · Cited by 60
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Compound heterozygotes of 15631T and another low activity allele (e.g. *11, *18, *27, *28) also predict high efavirenz plasma levels (Rotger et al., 2007; Ribaudo et al., 2010).”
BackgroundInfluentialSelf-citationIngelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.851949 · Cited by 651
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Self-citation
Metadata
- Authors
- Rotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., Eichelbaum, M., Telenti, A., & Zanger, U. M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-01-18
- Volume
- 81
- Issue
- 4
- Pages
- 557-566
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2109808952
- Cited by
- 257
- References
- 26
- FWCI
- 21.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.